MedTrace Logo

Desensitization of Renal Transplant Candidates

NCT00298883 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-07-25

No results posted yet for this study

Summary

Trial of the use of Myfortic to reduce anti-HLA alloantibody in patients waiting for renal transplantation.

Conditions

Interventions

DRUG

Myfortic

Myfortic 360mg PO BID for six weeks

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • Shiro Fujita, MD · University of Florida

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-08-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00298883 on ClinicalTrials.gov